CriticalReversible MAO-A inhibitor (RIMA)×Selective 5-HT1B/1D serotonin receptor agonist
Updated · Methodology
Mechanism
Monoamine oxidase type A (MAO-A) is the main enzyme that breaks down rizatriptan, and moclobemide reversibly inhibits mainly this enzyme (rizatriptan summary of product characteristics, SmPC, section 5.2; moclobemide SmPC, section 5.1). In subjects taking moclobemide 150 mg three times a day, the area under the concentration curve (AUC) of rizatriptan rose by a mean of 119% and its peak concentration by 41%. The AUC of the active metabolite N-monodesmethyl-rizatriptan rose by more than 400% (rizatriptan label, US Food and Drug Administration, FDA, section 12.3). Rizatriptan stimulates serotonin 5-HT1B and 5-HT1D receptors and can constrict intracranial blood vessels (rizatriptan SmPC, section 5.1). The moclobemide SmPC contraindicates all triptans because MAO and cytochrome P450 enzymes break them down, so their concentrations rise with moclobemide (section 4.5). The Spanish rizatriptan SmPC names the risk of coronary artery constriction and hypertensive crises as the reason for its contraindication (section 4.5).
Symptoms
Rizatriptan itself can cause chest tightness and pain, sometimes intense and spreading to the throat, as well as palpitations and raised blood pressure. Myocardial ischaemia and infarction occurred mostly in people with risk factors for coronary artery disease (rizatriptan summary of product characteristics, SmPC, sections 4.4 and 4.8). On rare occasions triptans have caused a marked rise in blood pressure, up to hypertensive crisis with acute impairment of organ systems, including in people with no history of hypertension (rizatriptan label, US Food and Drug Administration, FDA, section 5.8). With monoamine oxidase (MAO) inhibitors, serotonin syndrome may occur: agitation, hallucinations, coma, fast heart rate, labile blood pressure, high temperature, overactive reflexes, poor coordination, nausea, vomiting and diarrhoea (FDA rizatriptan label, section 5.7). Symptoms can start within minutes to hours of a new or higher dose of a serotonergic drug (FDA rizatriptan label, section 5.7).
Management
The combination is contraindicated. The moclobemide summary of product characteristics (SmPC) contraindicates triptans and names rizatriptan explicitly (sections 4.3 and 4.5), and the rizatriptan SmPC contraindicates monoamine oxidase (MAO) inhibitors (sections 4.3 and 4.5). The US Food and Drug Administration (FDA) rizatriptan label also contraindicates MAO type A inhibitors (sections 4 and 7.5). Start rizatriptan no earlier than 2 weeks after stopping moclobemide (rizatriptan SmPC, section 4.3; FDA label, section 4). The documents give the same interval for reversible and irreversible MAO inhibitors. No document says how long to wait before starting moclobemide after rizatriptan. Rizatriptan is also contraindicated on its own in moderately severe or severe hypertension and in untreated mild hypertension (rizatriptan SmPC, section 4.3). If the two drugs have nevertheless been taken together and signs of serotonin syndrome appear, stop rizatriptan (FDA rizatriptan label, section 5.7). For moclobemide, consider a lower dose or stopping it, depending on how severe the symptoms are (moclobemide SmPC, section 4.4). If chest pain and tightness suggest cardiac ischaemia, withhold further rizatriptan doses and assess the patient (rizatriptan SmPC, section 4.4).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Moclobemida, Manerix 300 mg (nº registro 60824) (2025)– AEMPS, CIMA, nº registro 60824 (Manerix 300 mg comprimidos recubiertos con película), revisión 06/2025, secciones 4.3, 4.5, 5.1 y 5.2
- AEMPS: Ficha técnica: Rizatriptán (nº registro 62289), sección 4.3 (2024)– AEMPS, CIMA, nº registro 62289 (Maxalt 10 mg comprimidos, Organon Salud), revisión 07/2024, secciones 4.3, 4.4 y 4.5
- FDA: MAXALT (rizatriptan benzoate) prescribing information (2026)– FDA, DailyMed setid 007b4644-e0e7-4863-9ae3-fe09676b3f5f (Organon), revisión 01/2026 (versión 4), secciones 4, 5.2, 5.5, 5.6, 5.8 y 7.2